Skip to main content
Study examines diabetes drug management before FDG-PET/CT scans
6/11/2019

Ninety-nine percent, 88% and 30% of 195 calls made under the guise of a family member booking a FDG-PET/CT scan for a grandmother with diabetes and cancer to 65 nuclear medicine scheduling lines didn't give prescan treatment instructions for long-acting insulin, metformin and short-acting insulin, respectively, according to a study in a radiology journal. Researchers also found that although 70% of those who answered calls appropriately recommended stopping short-acting insulin use before the scan, only 1% correctly instructed that long-acting insulin be withheld after midnight, while 47% of calls had no system for communicating the scan's details to patients.

Full Story: